Nav: Home

IOF review of impact of drug holidays on bone health

July 08, 2019

The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new International Osteoporosis Foundation (IOF) working group paper 'Fracture risk following intermission of osteoporosis therapy' published in the journal Osteoporosis International.

The widespread practice of recommending one to two year 'drug holidays' arose following concerns that long-term use of bisphosphonates is associated with rare side effects, namely atypical femoral fractures and osteonecrosis of the jaw. However, available evidence suggests that for patients who are at high risk of fracture the risk-benefit ratio is clearly in favour of treatment continuation, with approximately 100 new fragility fractures prevented for each of these adverse events.

Lead author, Prof. Elaine Dennison, of the MRC Lifecourse Epidemiology Unit, University of Southampton, UK, stated: "Our aim was to review the available literature to assess what evidence exists to inform decision making on drug holidays and to identify any indicators that might help clinicians decide whether to continue or discontinue therapy in individual patients."

In general, few studies have fully considered this topic. However, based on the available evidence in prospective and retrospective analyses, the authors found that after stopping bisphosphonate treatment there was higher risk of new non-vertebral fractures in women who had a total hip T-score below -2.5, and the risk of clinical vertebral fractures was approximately double. As well, rapid bone loss occurs following denosumab discontinuation, with the incidence of multiple vertebral fractures around 5%.

Studies that considered long-term continuation did not identify increased fracture risk, and reported only very low rates of adverse skeletal events such as atypical fractures.

Professor Serge Ferrari, co-author and Chair of the IOF Committee of Scientific Advisors added: "This review points to the need for a far more nuanced approach to drug holidays. Osteoporotic fractures can be life-threatening and have a devastating impact on quality of life. Doctors and patients must be aware that, particularly for individuals at high risk, the benefits of staying on treatment clearly outweighs the risk of rare side effects. Furthermore, it is important to understand that bisphosphonates and denosumab are fundamentally different types of treatment which require different approaches as discontinuation of denosumab results in rapid bone loss, at least in subjects not previously exposed to long-lasting bisphosphonates."

IOF President Prof. Cyrus Cooper, co-author, concluded: "The burden of osteoporotic fractures is very high and costly, resulting in disability and loss of independence in millions of older women and men worldwide. The efficacy of proven treatments is well established with fracture reduction in the order of 50% possible. Rather than practicing indiscriminate application of drug holidays, we encourage more informed decision making and appropriate counselling of high-risk patients on the individual benefits of treatment continuation versus cessation."
-end-
* E.M. Dennison, C. Cooper, J.A. Kanis, O. Bruyère, S. Silverman, E. McCloskey, B. Abrahamsen, D. Prieto-Alhambra, S. Ferrari, on behalf of the IOF Epidemiology/Quality of Life Working Group. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int (2019) https://doi.org/10.1007/s00198-019-05002-w

About IOF

The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF members, including committees of scientific experts as well as more than 240 patient, medical and research societies in 99 countries, work together to make fracture prevention and healthy mobility a worldwide heath care priority. http://www.iofbonehealth.orghttp://www.worldosteoporosisday.org @iofbonehealth

International Osteoporosis Foundation

Related Bisphosphonates Articles:

Osteoporosis drugs linked to reduced risk of premature death
A large cohort study has revealed a common osteoporosis drug significantly decreases premature mortality risk, likely related to a reduction in bone loss.
IOF review of impact of drug holidays on bone health
The impact of interruption of anti-osteoporosis treatment in patients on therapy with bisphosphonates or denosumab is reviewed in a new IOF Working Group paper.
Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.
Bisphosphonates increasingly prescribed to the women most likely to benefit
In recent years, women who start taking bisphosphonates (BPs) to treat osteoporosis and prevent fracture have trended from younger to older and from having osteopenia to having osteoporosis, researchers report.
US older women three times as likely to be treated for osteoporosis as men
Older women in the US are three times as likely to be treated for osteoporosis as men of the same age, reveals research published online in the Journal of Investigative Medicine.
The delicate balance of treating growing but brittle bones
Turning off a bone receptor protein could potentially treat osteoporosis in children without affecting bone growth.
Failure to discontinue medications can contribute to inappropriate prescribing
The continuation of drugs that are not intended to be taken indefinitely is a substantial and common problem that could contribute to over-medication, particularly in the elderly.
Study sheds light on atypical periprosthetic femoral fractures
Following surgery, some patients experience a broken bone around the implants of a total hip replacement--called a periprosthetic femoral fracture.
Investigating what keeps metastatic breast cancer in check
New evidence suggests that inflammation may help prevent growth of tumor cells that have spread, with important implications for clinical trials.
Fifteen percent of osteoporosis patients who take 'drug holidays' suffer bone fractures
A Loyola Medicine study has found that 15.4 percent of patients who take so-called 'drug holidays' from osteoporosis drugs called bisphosphonates experienced bone fractures.
More Bisphosphonates News and Bisphosphonates Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.